You are here: Home » News-CM » Companies » News
Business Standard

Glenmark Pharmaceuticals receives USFDA approval for Clobetasol Propionate Foam, 0.05%

Capital Market 

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending July 2019, the Olux‐E Foam, 0.05% market2 achieved annual sales of approximately $11.1 million.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, September 10 2019. 11:03 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU